NEW YORK, June 20: ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter. No deal is imminent for the “orphan” drugmaker, which has a market capitalization of 1.8 billion dollars, said two of the sources, who requested anonymity because they are not permitted to speak to the media. (agencies)
Follow our WhatsApp channel